1. Clinical & Scientific Overview
N-Acetylcysteine (Oral/Inhaled Mucolytic) & Ambroxol / Bromhexine (TIP-MED-000180, Reference Code [9.16]) is classified under
Respiratory, Asthma, COPD & Allergy Medicines (Ch 09) as a Sulfhydryl Disulfide-Bond Mucolytic + Glutathione Precursor & Mucokinetic Secretomotor Agents (Schedule H / OTC).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 09 [9.16], p. 121): N-Acetylcysteine (NAC): Mucinac (Cipla — 600 mg Effervescent Tab, 200 mg Sachet, 20% Respule/IV), Fluimucil. Ambroxol: Ambrodil (Aristo), Mucolite (Dr. Reddy's). Bromhexine: Bisolvon; FDCs: Ascoril LS, Bro-Zedex — Strengths & Dosage Forms: NAC Effervescent Tablets: 600 mg; Sachets/Tablets: 200 mg, 600 mg; Nebuliser/IV Solution: 200 mg/mL (20%). Ambroxol Tablets: 30 mg, 75 mg SR; Syrup: 15 mg/5mL, 30 mg/5mL
NAC Effervescent Tablets: 600 mg; Sachets/Tablets: 200 mg, 600 mg; Nebuliser/IV Solution: 200 mg/mL (20%). Ambroxol Tablets: 30 mg, 75 mg SR; Syrup: 15 mg/5mL, 30 mg/5mL
3. Mechanism of Action & Pharmacodynamics
Sulfhydryl Disulfide-Bond Mucolytic + Glutathione Precursor & Mucokinetic Secretomotor Agents (Schedule H / OTC) acting on target receptor/enzyme pathways in Respiratory, Asthma, COPD & Allergy Medicines (Ch 09): clinical efficacy is mediated via Sulfhydryl Disulfide-Bond Mucolytic + Glutathione Precursor & Mucokinetic Secretomotor Agents (Schedule H / OTC) for Productive cough with thick, viscid, tenacious mucus in acute/chronic bronchitis, COPD, bronchiectasis, cystic fibrosis, and pneumonia (NAC breaks mucoprotein disulfide [-S-S-] bonds; Ambroxol stimulates surfactant synthesis and mucociliary clearance).
4. Therapeutic Indications & Evidence-Supported Uses
- Productive cough with thick, viscid, tenacious mucus in acute/chronic bronchitis, COPD, bronchiectasis, cystic fibrosis, and pneumonia (NAC breaks mucoprotein disulfide [-S-S-] bonds
- Ambroxol stimulates surfactant synthesis and mucociliary clearance)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: NAC Oral: 600 mg Effervescent Tablet dissolved in half a glass of water PO Once or Twice Daily. Ambroxol: Adults: 30 mg PO BD–TDS (or 75 mg SR OD); Children (2–5 yr): 7.5 mg (2.5 mL) BD–TDS; (6–12 yr): 15 mg (5 mL) BD–TDS
Administration & Meal Timing: Dissolve NAC 600 mg effervescent tablet completely in 100–150 mL of water before drinking; take Ambroxol/Bromhexine AFTER meals with plenty of warm water. Take the evening dose BEFORE 5:00–6:00 PM (avoid taking a mucolytic right at bedtime!) | Morning & Afternoon/Early Evening (Avoid late bedtime dose!)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal & Hepatic: Safe at mucolytic doses; avoid high-sodium effervescent NAC tablets in severe salt-restricted HFrEF/cirrhosis/HTN (each 600 mg effervescent tablet contains ~140–190 mg of Sodium — use film-coated NAC tablets instead!)
Renal & Hepatic: Safe at mucolytic doses; avoid high-sodium effervescent NAC tablets in severe salt-restricted HFrEF/cirrhosis/HTN (each 600 mg effervescent tablet contains ~140–190 mg of Sodium — use film-coated NAC tablets instead!)
Renal & Hepatic: Safe at mucolytic doses; avoid high-sodium effervescent NAC tablets in severe salt-restricted HFrEF/cirrhosis/HTN (each 600 mg effervescent tablet contains ~140–190 mg of Sodium — use film-coated NAC tablets instead!)
7. Contraindications, Precautions & High-Risk Warnings
- CONTRAINDICATIONS & WARNINGS: (1) NEBULISED 20% NAC is hyperosmolar and acidic (pH 2.2) and can trigger SEVERE ACUTE BRONCHOSPASM in asthmatics — always co-administer with nebulised Salbutamol/Levosalbutamol! (2) Avoid mucolytics in patients with weak cough reflex (infants <2 years, neuromuscular weakness, coma). (3) Active peptic ulcer. (4) Rare SJS/TEN alert with Ambroxol/Bromhexine
Key Clinical Precautions: Renal & Hepatic: Safe at mucolytic doses; avoid high-sodium effervescent NAC tablets in severe salt-restricted HFrEF/cirrhosis/HTN (each 600 mg effervescent tablet contains ~140–190 mg of Sodium — use film-coated NAC tablets instead!)
8. Adverse Effects Profile
- Nausea, epigastric burning, rhinorrhoea, sulfur/rotten-egg odour (NAC — normal due to sulfhydryl SH group!)
- Bronchospasm (especially with nebulised NAC), haemoptysis, rare severe cutaneous adverse reactions (SJS/TEN with Ambroxol — stop immediately if prodromal fever + mucosal rash occurs!)
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- NEVER combine a Mucolytic (NAC/Ambroxol) with a Cough Suppressant / Antitussive (Dextromethorphan, Codeine, Levodropropizine) — suppressing the cough reflex while liquefying sputum causes dangerous mucus retention! NAC potentiates Nitroglycerin vasodilation
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: THREE COUNTER RULES: (1) Dissolve Mucinac 600 effervescent tablet in half a glass of water (if you have high BP or heart failure, ask for non-effervescent tablets to avoid the salt in fizzy tablets!); (2) Take the second dose in the early evening, NOT at bedtime; (3) Never mix a phlegm-loosening syrup with a dry-cough suppressant
- Meal & Clock Timing Instruction: Dissolve NAC 600 mg effervescent tablet completely in 100–150 mL of water before drinking; take Ambroxol/Bromhexine AFTER meals with plenty of warm water. Take the evening dose BEFORE 5:00–6:00 PM (avoid taking a mucolytic right at bedtime!) (Morning & Afternoon/Early Evening (Avoid late bedtime dose!))
- Missed Dose Protocol: Take in the morning/afternoon if missed; skip late night doses
- Geriatric Dispensing Pearl: Check cough strength in frail/stroke-affected older adults before giving mucolytics; monitor sodium load of effervescent tablets
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: NAC Effervescent Tablets: 600 mg; Sachets/Tablets: 200 mg, 600 mg; Nebuliser/IV Solution: 200 mg/mL (20%). Ambroxol Tablets: 30 mg, 75 mg SR; Syrup: 15 mg/5mL, 30 mg/5mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 09 [9.16] (p. 121)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [9.6]-C85 Ipratropium + Levosalbutamol / Salbutamol [FDC] — Short-Acting Muscarinic Antagonist (SAMA; 6-to-8 Hour Anticholine
- [9.8]-C86 Etophylline + Theophylline (Deriphyllin 77:23 FDC) — Methylxanthine Bronchodilator & Respiratory Stimulant (Non-Select
- [9.9]-C87 Cetirizine Dihydrochloride — Histamine H1-Receptor Inverse Agonists (Second-Generation Non-Sed
- [9.9]-C88 Chlorpheniramine Maleate (CPM) — Histamine H1-Receptor Inverse Agonists (Second-Generation Non-Sed
